Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apollomics Inc. - Warrant
(NQ:
APLMW
)
0.0169
+0.0002 (+1.20%)
Streaming Delayed Price
Updated: 11:06 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
500
Open
0.0169
Bid (Size)
0.0110 (1,000)
Ask (Size)
0.0169 (571)
Prev. Close
0.0167
Today's Range
0.0169 - 0.0169
52wk Range
0.0080 - 0.0989
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
August 14, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
August 13, 2024
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with...
From
Apollomics Inc.
Via
GlobeNewswire
Performance
YTD
-48.00%
-48.00%
1 Month
+69.00%
+69.00%
3 Month
-32.13%
-32.13%
6 Month
-44.41%
-44.41%
1 Year
-73.22%
-73.22%
More News
Read More
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
August 08, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
July 16, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
July 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentation at the 2024 BIO International Convention
May 29, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
May 08, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 25, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 10, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 28, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 26, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
January 19, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
January 17, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the 2024 Biotech Showcase
January 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 04, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
November 29, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 31, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 26, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.